June 23, 2021
Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Andrew Hotchkiss as Chief Executive Officer.
May 21, 2021
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol in the blood of test monkeys. In their paper published in the journal Nature, the researchers describe their technique.
May 11, 2021
Verve Therapeutics announced the presentation of additional preclinical data from the company's gene editing programs for the treatment of atherosclerotic cardiovascular disease, the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy 24th Virtual Annual Meeting.
May 5, 2021
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio),
April 21, 2021
Scientists at AstraZeneca have early data showing that an experimental antibody drug increases "good" HDL cholesterol in monkeys and people. Combining the drug with a PCSK9 inhibitor appeared to have a synergistic effect.